Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Stereotaxis Inc    STXS

News SummaryMost relevantAll newsSector newsTweets 

Stereotaxis, Inc. : Stereotaxis to Present at Oppenheimer Healthcare Conference in New York on December 13, 2012

share with twitter share with LinkedIn share with facebook
share via e-mail
12/06/2012 | 01:52pm CEST

ST. LOUIS, Dec. 6, 2012 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) today announced that Michael P. Kaminski, President and CEO, and Sam Duggan, CFO, will present at the Oppenheimer 23rd Annual Healthcare Conference on Thursday, December 13th at 2:45 p.m. ET. The conference is being held at the Waldorf-Astoria Hotel in New York City.

A live webcast and subsequent archived replay of the presentation will be accessible at www.stereotaxis.com within the "Investors" section. The replay will be available for 90 days after the event.

To arrange a one-on-one meeting with Stereotaxis management at the conference, please contact an Oppenheimer sales person, or the MKR Group, Stereotaxis' investor relations firm, at [email protected].

About Stereotaxis

Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. With over 100 patents for use in a hospital's interventional surgical suite, Stereotaxis helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced collaboration of life-saving information. Stereotaxis' core technologies are the Niobe® ES Remote Magnetic Navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management systems and the Vdrive™ Robotic Mechanical Navigation system and consumables.

The core components of Stereotaxis systems have received regulatory clearance in the U.S., Europe, and Canada and elsewhere; the V-Loop™ circular catheter manipulator is currently in human clinical trials and V-Sono™ ICE catheter manipulator is  under regulatory review by the U.S. Food and Drug Administration. For more information, please visit www.stereotaxis.com and www.odysseyexperience.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, our continued access to capital and financial resources on a timely basis and on terms that are acceptable, our continued listing on the Nasdaq Global Market, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, the outcome of various shareholder litigation recently filed against us, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

CONTACT: Company Contact:
         Sam Duggan
         Chief Financial Officer

         Investor Contact:
         Todd Kehrli / Jim Byers
         MKR Group, Inc.

         Media Contact:
         Frank Cheng
         Senior Vice President,
         Marketing & Business
Stereotaxis, Inc.
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on STEREOTAXIS INC
06/16 STEREOTAXIS : Launches the e-Contact Module in Europe
06/15 Stereotaxis Launches the e-Contact™ Module in Europe
05/26 STEREOTAXIS, INC. (OTCMKTS : STXS) Files An 8-K Departure of Directors or Certai..
05/08 STEREOTAXIS, INC. (OTCMKTS : STXS) Files An 8-K Results of Operations and Financ..
05/08 Stereotaxis Reports 2017 First Quarter Financial Results
05/08 STEREOTAXIS INC : Investor Network: Stereotaxis, Inc. to Host Earnings Call
04/27 Stereotaxis to Report First Quarter 2017 Financial Results on May 8, 2017
04/25 Stereotaxis’ Leadership in Robotic Cardiac Ablation to be Showcased at ..
04/18 STEREOTAXIS : pays ex-CEO $489,000 in severance
03/15 STEREOTAXIS : Clinical Study Validates Efficiencies of Stereotaxis Niobe ES Syst..
More news
Sector news : Advanced Medical Equipment & Technology - NEC
09:03a Philips to buy medical device maker Spectranetics for 1.9 billion euros
08:45a Philips to buy medical device maker Spectranetics for 1.9 billion euros
08:24aDJROYAL PHILIPS : to Buy Spectranetics for $2.15 Billion
06/22DJROYAL PHILIPS : Philips to Buy Electrical Geodesics for GBP29 Million
06/19 PERKINELMER : to buy Germany's Euroimmun for about $1.3 billion
More sector news : Advanced Medical Equipment & Technology - NEC
News from SeekingAlpha
2016 Midday Gainers / Losers
2016 Stereotaxis installs Niobe ES system at leading pediatric hospital; shares up..
2016 Stereotaxis' (STXS) CEO Bill Mills on Q1 2016 Results - Earnings Call Transcr..
Duration : Period :
Stereotaxis Inc Technical Analysis Chart | STXS | US85916J4094 | 4-Traders
Full-screen chart
Mean consensus
Number of Analysts
Average target price -
Spread / Average Target -100%
Consensus details
David Andrew Fischel Chairman & Chief Executive Officer
Martin C. Stammer Chief Financial Officer
Paul A. Brathwaite Vice President-Research & Development
Fred A. Middleton Independent Director
David W. Benfer Lead Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
DANAHER8.71%59 950
ROYAL PHILIPS12.21%34 752
More Results